Compare CHGG & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHGG | CSBR |
|---|---|---|
| Founded | 2005 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4M | 90.0M |
| IPO Year | 2013 | 1986 |
| Metric | CHGG | CSBR |
|---|---|---|
| Price | $0.94 | $6.72 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $1.42 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.7M | 9.1K |
| Earning Date | 11-10-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.21 |
| Revenue | ★ $447,733,000.00 | $56,878,000.00 |
| Revenue This Year | N/A | $7.31 |
| Revenue Next Year | N/A | $12.01 |
| P/E Ratio | ★ N/A | $31.49 |
| Revenue Growth | N/A | ★ 10.11 |
| 52 Week Low | $0.44 | $4.61 |
| 52 Week High | $2.40 | $11.99 |
| Indicator | CHGG | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 58.38 |
| Support Level | $0.83 | $6.16 |
| Resistance Level | $0.99 | $6.43 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 56.50 | 73.08 |
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.